EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites

Contributed by: PR Newswire

Tags

EMA-Approves-Biocon

More Like This

WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

PR Newswire associated0

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations

PR Newswire associated0

GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing

Merck invests €70 million to triple its antibody-drug conjugate (ADC) manufacturing capacity and upgrade 3200 m2 at its BioConjugation Center of Excellence in St. Louis, Missouri, USA. (Photo: Business Wire)

Merck Invests €70 Million to Expand ADC Manufacturing for Novel Cancer Therapies

Business Wire logo

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Business Wire logo

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

PR Newswire associated0

PIRAMAL PHARMA SOLUTIONS COMMEMORATES OPENING OF ITS ADC MANUFACTURING EXPANSION IN GRANGEMOUTH, SCOTLAND